Computed tomography (CT)-guided percutaneous combined with microwave ablation and 125I seed implantation for the treatment of advanced and metastatic lung cancer
DH. Chena (Ms), B. Caib (Dr), J. Chenc (Dr), X. Xud (Ms), SX. Lic (Ms), B. Yuane (Prof), RD. Xuf (Prof), J. Li*g (Prof)
a Baiyun Branch of Nanfang Hospital, Guangzhou, CHINA ; b Dali university, Dali,Yunnan,China., Yunnan, CHINA ; c Department of Pulmonary and Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences. Guangzhou, Guangdong, China., Guangzhou, CHINA ; d 4.Department of Pulmonary and Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences. Guangzhou, Guangdong, China., Guangzhou, CHINA ; e Department of Pulmonary and Critical Care Medicine,The First People's Hospital of Yunnan Province. The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China, Kunming, CHINA ; f Department of Comprehensive interventional Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences. Guangzhou, Guangdong, China., Kunming, CHINA ; g Department of Pulmonary and Critical Care Medicine,The First People's Hospital of Yunnan Province. The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China., Kunming, CHINA
* dr.lijing@gdph.org.cn
Objective: To investigate and analyze the clinical efficacy of CT guided microwave ablation (MWA) combined with 125I seed implantation in the treatment of lung malignancies.
Methods: Records of Forty-four patients, who were followed up for advanced or metastatic lung cancer treated with MWA or MWA combined with 125I seed implantation from January 2015 to December 2020 in Guangdong Provincial People's Hospital, were retrospectively reviewed, 28 patients were treated with MWA (MWA group) and 16 patients were treated with MWA combined with 125I seed implantation (Combined group). The recent outcomes, complications, Karnofsky score (KPS), survival and factors associated with survival were compared between the two groups of patients.
Results: The effective rate was 21.43% in the MWA group and 56.25% in the combined group, P < 0.05; The complication rate was 46.43% in MWA patients and 62.50% in combined group, P > 0.05; KPS score was lower than before treatment in both groups (P < 0.05) after treatment in one month. KPS score in combined group was higher than before treatment in this group after treatment in three months, and also much higher than MWA group scores in the same period (P < 0.05). The combined group showed higher median survival time than MWA group (32.00 (14.749,49.251) vs 12.009 (9.273,14.727) months respectively ;P < 0.05) . The factors associated with survival were subjected to Cox regression, which the protective factors were treatment modality [HR=0.400, 95% CI (0.849,0.957), P=0.048] and preoperative KPS [HR=0.902, 95% CI (0.85049, 0.957), P=0.001].
Conclusion: CT-guided MWA combined with 125I seed implantation is safe and effective in the treatment of advanced and metastatic lung cancer, which can control its progression and prolong survival time.
Disclosure of funding source(s):
This research was supported by The Major Science and Technology Special Program Fund of Yunnan Biomedical Special Program (No.:202102AA100012).